HEMATOPOIETIC STEM CELL TRANSPLANTATION: Edited by Pavan ReddyAdvances in chimeric antigen receptor T cellsBeyar-Katz, Ofrata; Gill, Saara,bAuthor Information aCenter for Cellular Immunotherapies bDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA Correspondence to Saar Gill, Smilow Translational Research Center, 8-101, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Tel: +1-215-573-4015; e-mail: firstname.lastname@example.org‘ Current Opinion in Hematology: November 2020 - Volume 27 - Issue 6 - p 368-377 doi: 10.1097/MOH.0000000000000614 Buy Metrics Abstract Purpose of review To discuss the important advances in CAR T cell therapy over the past year, focusing on clinical results where available. Recent findings Approximately 30 years after they were first conceived of and 15 years after the first small-scale single-center clinical trials, the past 3 years represent a major milestone in the development of CAR T cells. In the United States, the Food and Drug Administration (FDA) approved Tisagenlecleucel for the treatment of relapsed/refractory B-ALL and Axicabtagene Ciloleucel, for adults with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) in 2017. Tisagenlecleucel received a second indication in adults with R/R DLBCL in 2018. Regulatory approval for CAR T cells was then granted in Europe, Canada, Australia, and Japan. Most recently, in July 2020 the FDA granted regulatory approval to a third CAR T cell product, Brexucabtagene Autoleucel for mantle cell lymphoma. All products target the CD19 antigen but differ in the costimulatory molecule within the CAR construct. Currently, it is unknown whether there are any differences in clinical activity or toxicity between these products. Summary The CAR T cell the platform is evolving at a rapid pace and is expected to further improve the therapeutic outcomes of hematological malignancies. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.